Evidence Hub

Ticagrelor-Induced Dermatological Hypersensitivity Reaction

Lunge S, Doshi SR, Sardesai VR

Cureus, 2025

Abstract

Ticagrelor, a potent antiplatelet medication widely used in acute coronary syndromes, is known for its favourable efficacy and safety profile as compared to clopidogrel. However, skin-related adverse events associated with ticagrelor are rare and not extensively reported in the literature. Here we present a 64-year-old male with a history of coronary artery disease and recent ticagrelor initiation following percutaneous coronary intervention. The patient developed a diffuse erythematous rash involving the trunk and extremities, two days post-ticagrelor initiation, prompting a thorough evaluation for drug-induced hypersensitivity reactions. The rash resolved upon discontinuation of ticagrelor and initiation of clopidogrel therapy along with corticosteroids and antihistamines. This case highlights the importance of recognizing dermatology adverse events associated with ticagrelor.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free